# A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

Study · id `cardio:ct-nct02293395` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02293395](<https://clinicaltrials.gov/study/NCT02293395>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02293395

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3037 participants.

## Technical summary

Registry record NCT02293395. Randomized; double masking; primary purpose treatment. Start 2015-04-20 (actual); primary completion 2016-10-14 (actual). Results posted on 2017-11-13.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 3037 participants (enrolled count; ClinicalTrials.gov record NCT02293395, source copy `cardio:ctgov-nct02293395-2017-12-26`, retrieved 2026-10-26)
- Started: 2015-04-20 (actual) (ClinicalTrials.gov record NCT02293395, source copy `cardio:ctgov-nct02293395-2017-12-26`, retrieved 2026-10-26)
- Primary completion: 2016-10-14 (actual) (ClinicalTrials.gov record NCT02293395, source copy `cardio:ctgov-nct02293395-2017-12-26`, retrieved 2026-10-26)
- Completion: 2016-10-14 (actual) (ClinicalTrials.gov record NCT02293395, source copy `cardio:ctgov-nct02293395-2017-12-26`, retrieved 2026-10-26)
- Results first posted: 2017-11-13 (ClinicalTrials.gov record NCT02293395, source copy `cardio:ctgov-nct02293395-2017-12-26`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Belgium; Brazil; Bulgaria; Canada; Czechia; Denmark; France; Hungary; Japan; Netherlands; Poland; Russia; South Korea; Spain; Sweden; Türkiye; Ukraine (ClinicalTrials.gov record NCT02293395, source copy `cardio:ctgov-nct02293395-2017-12-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02293395-2017-12-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome
- Acronym: GEMINI ACS 1
- Condition: Acute Coronary Syndrome
- Intervention (Drug): Acetylsalicylic acid
- Intervention (Drug): Rivaroxaban
- Intervention (Drug): Clopidogrel
- Intervention (Drug): Ticagrelor
- Lead sponsor: Janssen Research & Development, LLC
- Lead sponsor class: INDUSTRY
- Collaborator: Bayer
- Collaborator class: INDUSTRY
- Collaborator: Duke Clinical Research Institute
- Collaborator class: OTHER
- Collaborator: Harvard Medical School (HMS and HSDM)
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Unstable angina (`cardio:unstable-angina`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry intervention name matches this record: Rivaroxaban (`cardio:rivaroxaban`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry intervention name matches this record: Ticagrelor (`cardio:ticagrelor`)
- Registry lists this organization as the lead sponsor: Janssen Research & Development, LLC (`cardio:org-janssen-research-development-llc`)
- Registry lists this organization as a collaborator: Bayer (`cardio:bayer`)
- Registry lists this organization as a collaborator: Duke Clinical Research Institute (`cardio:org-duke-clinical-research-institute`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial (`cardio:pubmed-28325638`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes (`cardio:pubmed-31141104`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 228be99d12622e4b245ce096f9d3d4ef6f827865ecb4c65afa68b7f40d13d67d
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
